Document is current
Any future updates will be listed below
-
Authors
Corriveau-Lecavalier, Nick
Li, Wentao
Ramanan, Vijay K.
Drubach, Daniel A.
Day, Gregory S.
Jones, David T. https://orcid.org/0000-0002-4807-9833
- License Information
-
More Information
Article History
Received: 13 December 2021
Revised: 16 February 2022
Accepted: 18 February 2022
First Online: 1 March 2022
Declarations
:
: GS Day is supported by a career development grant from the NIH (K23AG064029). He owns stock (> $10,000) in ANI Pharmaceuticals (a generic pharmaceutical company). He serves as a topic editor for DynaMed (EBSCO), overseeing development of evidence-based educational content, and as the Clinical Director of the Anti-NMDA Receptor Encephalitis Foundation (Inc, Canada; uncompensated).
: This retrospective study was approved by the Mayo Clinic Institutional Review Board.
: All patients or their informant provided written consent for their clinical data to be used for research purposes.
